Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback